Navigation Links
OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category
Date:10/9/2009

BOTHELL, WA, and VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that Scott Cormack, president and chief executive officer of OncoGenex, has been named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R). The Ernst & Young Entrepreneur Of The Year(R) Award is a high profile business award recognizing entrepreneurs that are building successful, dynamic businesses.

"I share this award with our co-founder Dr. Martin Gleave and all of our employees at OncoGenex, whose contributions and exceptional dedication to our programs have led to a series of major clinical and business advancements over the past 12 months," said Scott Cormack, President and CEO of OncoGenex.

"Over the past year, we have presented impressive data from the clinical trials of our lead drug candidate, OGX-011, for the treatment of advanced prostate cancer; reached agreements with the FDA on the design of two Phase 3 trials for evaluating OGX-011 treatment in advanced prostate cancer via the FDA's special protocol assessment process; received Fast Track designations from FDA for OGX-011 in combination with both first-line and second-line chemotherapy in advanced prostate cancer, which are expected to streamline the regulatory review process; presented data from our Phase 1 clinical trial evaluating our second product candidate, OGX-427; and initiated another clinical trial with OGX-427 in bladder cancer," Cormack said.

"For the remaining 2009 year, we are committed to securing a partner to support the final stage of development of OGX-011 and announcing additional development initiatives for our other product candidates."

Ernst & Young's Entrepreneur Of The Year(R) Award encourages entrepreneurial activity among those with potential and recognizes the contribution
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... septembre 2014 Mapi, société créée à ... a été depuis 40 ans l,un des ... traditionnelles par des évaluations recentrées sur le ... impacts économiques des traitements. Logo ... A cours d,une récente conférence téléphonique avec ...
(Date:9/18/2014)... 18, 2014 OMICS Group International ... to participate in the ‘Open Access Week’ by ... OMICS Group Pharma Journals from 20-26th ... the fastest emerging Sciences, accelerating with a tremendous ... across the globe. The industry is gearing with ...
(Date:9/18/2014)... is a group of rare diseases that afflict ... Its onset hits at the fetal stage and ... the gene encoding fibroblast growth factor receptor 3 ... skeletal dysplasia, thanatophoric dysplasia (TD), a skeletal dysplasia ... is often lethal, and achondroplasia (ACH), which causes ...
(Date:9/18/2014)... Artificial sweeteners, promoted as aids to weight loss and ... intolerance and metabolic disease; and they do it in ... of the gut microbiota the substantial population of ... of experiments in mice and humans, were published today ... Eran Elinav of the Weizmann Institute,s Immunology Department, who ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3
... Israel and NEW YORK, October 2 ... on,Company,s Diagnostic and Therapeutic Development Programs, as Well ... (Nasdaq: ROSG ), a global leader in,microRNA-based ... R&D Day on microRNAs and their significant potential ...
... /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a ... of technologies targeting the chronic inflammation,underlying cardiovascular and ... close of the North American financial markets,on Tuesday, ... web cast will also,be conducted on Tuesday, October ...
... 2 Othera Pharmaceuticals, Inc., a,specialty pharmaceuticals ... oncology, and inflammatory disease, has,announced the appointment ... Chief,Scientific Officer effective immediately. In this position, ... execution of Othera,s research,and clinical development programs. ...
Cached Biology Technology:Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007 2Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007 3Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007 4Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 2Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 3Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 4Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer 2Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer 3
(Date:9/18/2014)... and their colleagues have built the first smartphone ... performance and behavioral trends. In other words, your ... if you don,t -- and how that affects ... happiness, stress, depression and loneliness to their academic ... population for example, to monitor mental health, ...
(Date:9/18/2014)... algal forests in the eastern Mediterranean Sea pose a ... distribution continues to expand as the climate warms, a ... of researchers led by Dr Adriana Vergs of UNSW ... for Advanced Studies in Spain, is published in the ... surveyed more than 1000 kilometres of coastline in Turkey ...
(Date:9/18/2014)... ultimate form of camouflage: you don,t just blend in, ... not as uncommon as you might think. Kathryn Feller, ... that the larval life stages of many marine species ... anatomy that most creatures cannot make transparent. Feller explains ... each individual eye unit with an opaque pigment to ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2Transparent larvae hide opaque eyes behind reflections 2
... can counteract the effects of tumor-promoting molecules in skin ... University of Pennsylvania School of Medicine. Using animal models, ... in epithelial cells, preventing uncontrolled cell growth caused by ... published online in the Journal of Biological Chemistry, suggests ...
... suffering chronic obstructive pulmonary disease (COPD) attempt to ... contradicts the conventional wisdom on the capabilities of ... attempted regional elastic fiber repair in severe emphysema," ... Patterson and Richard Pierce of Washington University, St. ...
... neurons may have been a key factor in why ... primate relatives. In a study comparing the genomes of ... U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley ... high degree of genetic differences in DNA sequences that ...
Cached Biology News:Signal protein shows promise for blocking tumor promoters in skin cells 2Lungs try to repair damaged elastic fibers 2Neuron cell stickiness may hold key to evolution of the human brain 2Neuron cell stickiness may hold key to evolution of the human brain 3Neuron cell stickiness may hold key to evolution of the human brain 4
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside ... Br Cl N O 6 ... (HPLC) ,Solution: Clear (2% in DMF) ... pUC and M13 ,Elemental Analysis: Agrees ...
Antibodies were affinity purified using epitopes specific to RFC1 immobilized on solid support....
Biology Products: